A new cereblon E3 ligase modulator shows promising results with complete response in highly refractory multiple myeloma patients
At EHA 2021, Professor Sagar Lonial from the Winship Cancer Institute, Atlanta, presented results from an ongoing Phase 1/2 study in patients with relapsed/refractory multiple myeloma, treated with immunomodulatory drug iberdomid. This paves the way for phase III combination studies.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
